These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 20446797)

  • 1. Comment on: Recurrent skin reaction attributable to darbepoetin alfa in a patient with chronic renal failure.
    Cholongitas E; Spyrou S; Georgousaki C; Dasenaki M
    Ren Fail; 2010 May; 32(4):528. PubMed ID: 20446797
    [No Abstract]   [Full Text] [Related]  

  • 2. Recurrent skin reaction secondary to darbepoetin alfa for two months in a patient with chronic lymphocytic leukemia.
    Jabr FI; Taher A
    Am J Hematol; 2007 Mar; 82(3):245. PubMed ID: 16955458
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F; Oliveira L; Maia P; Mendes T; Ferreira C
    Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darbepoetin alfa and chronic kidney disease.
    Minnerup J; Schäbitz WR
    N Engl J Med; 2010 Feb; 362(7):653-4; author reply 655. PubMed ID: 20187258
    [No Abstract]   [Full Text] [Related]  

  • 5. Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.
    Einarson T; Machado M; Walker J; Iskedjian M
    Curr Med Res Opin; 2007 Jul; 23(7):1571-3; author reply 1573-4. PubMed ID: 17637205
    [No Abstract]   [Full Text] [Related]  

  • 6. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study.
    Bommer J; Asmus G; Wenning M; Bommer G
    Nephrol Dial Transplant; 2008 Dec; 23(12):4002-8. PubMed ID: 18676350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darbepoetin alfa and chronic kidney disease.
    Hampl H; Kovesdy CP; Kalantar-Zadeh K
    N Engl J Med; 2010 Feb; 362(7):654; author reply 655. PubMed ID: 20187260
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.
    Roger SD; Suranyi MG; Walker RG; Disney A; Isbel NM; Kairaitis L; Pollock CA; Brown FG; Chow J; Truman MI; Ulyate KA;
    Curr Med Res Opin; 2008 Aug; 24(8):2181-7. PubMed ID: 18565240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
    Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
    Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
    Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa.
    Pannier A; Jordan P; Dougherty FC; Bour F; Reigner B
    Curr Med Res Opin; 2007 Dec; 23(12):3025-32. PubMed ID: 17961301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
    J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients.
    Hiramatsu M; Kubota M; Iwasaki M; Akizawa T; Koshikawa S;
    Ther Apher Dial; 2008 Feb; 12(1):19-27. PubMed ID: 18257808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TREAT study answers a question, not the question.
    Coyne DW
    Am J Kidney Dis; 2008 Sep; 52(3):626-7; author reply 627-8. PubMed ID: 18725019
    [No Abstract]   [Full Text] [Related]  

  • 17. Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis.
    Asari A; Gokal R
    J Am Soc Nephrol; 2004 Aug; 15(8):2204-7. PubMed ID: 15284306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin.
    Kamar N; Guitard J; Ribes D; Esposito L; Rostaing L
    Exp Clin Transplant; 2008 Dec; 6(4):271-5. PubMed ID: 19338488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
    Hörl WH; Holzer H; Mayer GJ;
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):967-71. PubMed ID: 12635463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.